CurrentCignaPolicy N/A

Inflammatory Conditions - Tocilizumab Subcutaneous Products Prior Authorization Policy

Cigna prior authorization policy governing coverage and medical necessity criteria for subcutaneous tocilizumab products (Actemra SC and Tyenne SC) across FDA-approved indications and select other supported uses; includes required prescriber specialty, initial vs continuation criteria, approval durations, and not medically necessary combinations/uses.

Policy Summary

PayerCigna

PolicyInflammatory Conditions - Tocilizumab Subcutaneous Products Prior Authorization Policy

Policy CodePolicy N/A

Change TypeSelected revisionproduct additionannual administrative review

Effective DateN/A

Next Review DateN/A

Key ActionPrior Authorization is recommended; ensure requests meet the indication-specific criteria and required specialist involvement and document duration on therapy and clinical response for continuation approvals.

SourceLink

POLICY UPDATE CHANGES

Selected Revision 06/11/2025: Giant Cell Arteritis initial corticosteroid requirement changed to 'tried or is currently taking' a systemic corticosteroid, and SJIA note added aligning SJIA and AOSD.

Selected Revision 06/26/2024: Tyenne subcutaneous was added with same criteria as other tocilizumab subcutaneous products.

Annual Revision - No criteria changes (04/23/2025).

7Covered Indications (listed)

6m/1yApproval Durations (initial/continuation)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1Not Covered: concurrent biologic/targeted synthetic

Coverage Summary

Tocilizumab subcutaneous products (Actemra® and Tyenne®) are IL-6 receptor inhibitors used to treat multiple inflammatory conditions. FDA‑approved indications covered by this policy include giant cell arteritis (adults), interstitial lung disease associated with systemic sclerosis (SSc‑ILD, adults), polyarticular juvenile idiopathic arthritis (≥ 2 years), rheumatoid arthritis (adults), and systemic juvenile idiopathic arthritis (≥ 2 years); the policy also includes select other supported uses (e.g., polymyalgia rheumatica, Still’s disease/AOSD). Prior authorization is recommended and initial approvals require prescription by or consultation with a specialist appropriate to the treated condition (e.g., rheumatologist or pulmonologist). Coverage stance: covered_with_criteria.

Quick facts — tocilizumab subcutaneous policy

Covered Indications7

Not Covered CategoryConcurrent use with another biologic or targeted synthetic oral small molecule

Approval DurationsInitial: 6 months; Continuation: 1 year

Giant Cell Arteritis age threshold> 18 years

PJIA and SJIA age threshold> 2 years

Rheumatoid Arthritis age threshold> 18 years

SSc-ILD lab/FVC thresholdsAt least one: CRP ≥ 6 mg/mL, or ESR ≥ 28 mm/h, or Platelets ≥ 330 x10^9/L; and FVC > 55% predicted

Medical Necessity Criteria (by indication)

Not Medically Necessary / Exclusions

The policy states that tocilizumab should not be administered concurrently with another biologic or with a targeted synthetic oral small molecule drug for an inflammatory condition; such concurrent use is considered not medically necessary. Providers should follow prior authorization requirements and indication‑specific criteria; claims for combinations listed as not medically necessary may be denied if billed. Initial approvals require specialist prescribing or consultation, and reviewers will apply the policy language when assessing medical necessity for combination therapy.

Denial Risk

Not medically necessary combinations

Use is considered not medically necessary if administered concurrently with another biologic or with a targeted synthetic oral small molecule drug for an inflammatory condition; claims may be denied if such combinations are billed.

Another biologic
Targeted synthetic oral small molecule

Coding

Products covered under policymixedCovered

Actemra (tocilizumab subcutaneous injection)	Genentech/Roche product covered per criteria
Tyenne (tocilizumab-aazg subcutaneous injection)	Fresenius Kabi product covered per criteria

Provider Actions & Documentation Requirements

Prior Authorization

Prior authorization required

Prior Authorization is recommended for tocilizumab subcutaneous products; requests must meet the applicable indication-specific criteria and approvals are for specified durations (6 months for initial therapy or 1 year for established therapy).

Initial approval duration: 6 months
Continuation/established therapy duration: 1 year

Documentation Required

Specialist involvement required

Initial approval requires the medication be prescribed by or in consultation with a physician who specializes in the condition being treated (e.g., rheumatologist or pulmonologist where specified).

Documentation Required

Background, Evidence & Definitions

Tocilizumab is an interleukin‑6 (IL‑6) receptor inhibitor with FDA‑approved indications across several inflammatory diseases. Clinical guidelines (ACR, EULAR, EULAR/PReS) reference IL‑6 blockade in multiple indications, and pivotal trials support efficacy—for example, the GiACTA trial demonstrating higher sustained remission rates in giant cell arteritis with tocilizumab plus prednisone taper vs prednisone taper alone, and a pivotal SSc‑ILD trial showing less decline in FVC% predicted at Week 48 with tocilizumab versus placebo. The policy appendix lists tocilizumab products and their IL‑6 mechanism of action.

Study/Endpoint	Key Result
GiACTA trial (Giant Cell Arteritis) - Sustained remission at Week 52	56% with weekly tocilizumab + 26-week prednisone taper vs 14% with 26-week prednisone taper
SSc-ILD pivotal trial - Change in FVC% predicted at Week 48	Tocilizumab: 0.07 vs Placebo: -6.40

Revision History

06/26/2024selected_revision

Tyenne subcutaneous (tocilizumab-aazg) was added to the policy with the same criteria as other tocilizumab subcutaneous products; product list expanded to include biosimilar/alternate manufacturer.

04/23/2025annual_review

Annual review completed with no criteria changes.

06/11/2025selected_revisionLatest

Policy Summary

PayerCigna

PolicyInflammatory Conditions - Tocilizumab Subcutaneous Products Prior Authorization Policy

Policy CodePolicy N/A

Change TypeSelected revisionproduct additionannual administrative review

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Establishment on therapy and response documentation for continuation

For continuation approvals, document duration on therapy (≥6 months for most indications, ≥1 year for SSc-ILD continuation assessment) and objective evidence of beneficial clinical response or symptom improvement compared with baseline.

Examples of objective measures: CRP, ESR, FVC, disease activity scores (e.g., CDAI, DAS28, JADAS)

Documentation Required

Corticosteroid trial requirement for certain conditions

For Giant Cell Arteritis and Polymyalgia Rheumatica initial therapy, document prior or current use of a systemic corticosteroid unless contraindicated.

Applicable conditions: Giant Cell Arteritis
Polymyalgia Rheumatica

Documentation Required

DMARD or biologic trial requirement for RA and PJIA

For RA initial therapy document trial of one conventional synthetic DMARD for ≥3 months (exceptions if prior biologic trial exists); for PJIA document trial of one other systemic therapy or concurrent initiation with specified DMARDs or contraindication to those agents.

Rheumatoid Arthritis: conventional synthetic DMARD ≥3 months (or prior 3-month biologic trial exception)
Polyarticular Juvenile Idiopathic Arthritis: trial of one other systemic therapy OR concurrent start with methotrexate, sulfasalazine, or leflunomide, or contraindication to those agents

Material clarification: For Giant Cell Arteritis initial therapy the corticosteroid requirement was changed to 'has tried or is currently taking' a systemic corticosteroid unless contraindicated; SJIA note added aligning SJIA and AOSD and removing prior trial of one other systemic therapy for SJIA/AOSD.